The series C for Utah-founded drug discovery platform creator Recursion included capital from University of Minnesota and Texas Tech University System.

Recursion Pharmaceuticals, a US-based biotech discovery platform and drug developer spun out of University of Utah, closed a $121m series C round yesterday featuring University of Minnesota and Texas Tech University System.
The round was led by investment firm Baillie Gifford’s Scottish Mortgage Investment Trust, and also featured Mubadala Ventures, the venture fund established by telecoms firm SoftBank and Abu Dhabi state investment firm Mubadala.
Venture firms Lux Capital, Data Collective (DCVC), and Obvious Ventures also took part…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?